Xconomy.com -- Investors haven’t completely turned their backs on gene therapy, at least not on Celladon. The San Diego-based company raised another $2.8 million in recent weeks to keep operating until it sees results from a clinical trial that will show whether it has a groundbreaking gene therapy for people with congestive heart failure.
